Program
glumetinib
Also written as “Glumetinib”, “Gumarontinib Tablets” and “Glumetinib Tablets”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Drug pageGlumetinib: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haihe Biopharmaits history only | 51 open or running | phase 2since Aug 7, 2019 | Aug 7, 2017 | none ahead |
| CSPC Pharmaceutical Group | 33 open or running | phase 3since Feb 11, 2025 | Jul 18, 2024 | Dec 25, 2026phase 2 · NCT06525350 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CSPC Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 18, 2024First study: phase 2 study in RecurrenceFirst studyNCT06525350 · 256 planned
- Feb 11, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06829459 · 350 planned · China
- Mar 27, 2025Phase 3 study in RecurrenceNCT06908772 · 390 planned
Ahead
- Dec 25, 2026Primary completion: phase 2 study in RecurrenceNCT06525350
- Feb 15, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06829459
- Dec 31, 2028Primary completion: phase 3 study in RecurrenceNCT06908772
TargetBeta
“An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule
Other programs on MET
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Crizotinibrule | Pfizer | phase 4 | 31 |
| telisotuzumab adizutecan | AbbVie | phase 3 | 18 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| vebreltinibrule | beijing-pearl-biotechnology-limited-liability-company | phase 3 | 9 |
| vilzemetkib | Sino Biopharmaceutical | phase 3 | 8 |
| dalmelitinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| SHR-1826 | Jiangsu HengRui Medicine | phase 2 | 7 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
Studies
All 3 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06908772Recurrence | 3 | Not yet recruiting | Dec 31, 2028 | 390 |
| NCT06829459Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Feb 15, 2028 | 350 |
| NCT06525350Recurrence | 2 | Not yet recruiting | Dec 25, 2026 | 256 |
How it is read
Names in the registry
- “Glumetinib”, 4 entries
- “Gumarontinib Tablets”, 2 entries
- “Glumetinib Tablets”, 1 entry
- “Glumetinib tablets”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.